Burgdorf - Ypsomed, the leading independent developer and manufacturer of custom-made injection pens for pharmaceutical and biotech companies, and one of the leading suppliers of pen needles, is focusing future investments on its core business.
Burgdorf - OptiClik, developed and manufactured by Ypsomed, is the first "semi-disposable" insulin pen-system now launched by Sanofi-Aventis for its long-acting insulin Lantus in the US market. The market launch of OptiClik is a major milestone within Ypsomed's growth strategy.
Burgdorf-The offering of shares in Ypsomed Holding AG attracted high investor interest and was 7.6 times covered. The issue price for one registered share in Ypsomed Holding AG was set at CHF 68.00. Shares will be trading on the SWX Swiss Exchange for the first time today.
Burgdorf-The price range for registered shares in Ypsomed Holding AG will be CHF 60 to CHF 68 per share. The offering period will last from 10 to 21 September 2004, 12.00 am. The first day of trading on the SWX Swiss Exchange is planned for 22 September 2004.